Rheumatologic Medication Use During Pregnancy.
Rheumatologic Medication Use During Pregnancy.
复制标题
DOI：
10.1097/aog.0000000000003755
复制
发表时间：
2020-05
影响因子：
7.2
通讯作者：
Bettendorf B
中科院分区：
文献类型：
--
作者：
Peterson EA;Lynton J;Bernard A;Santillan MK;Bettendorf B
慢性风湿性疾病通常发生在育龄妇女中，妊娠对风湿性疾病的影响通常因病情而异。妊娠期风湿性疾病的医疗管理可以防止关节或器官损伤，并尽量减少疾病本身对妊娠结局的不良影响。每个患者都需要单独评估以控制疾病活动，同时尽量减少或避免使用具有潜在母体或胎儿毒性的药物。在患者、产科医生、风湿病学家和药剂师之间进行公开讨论，共同做出决策，对于制定符合患者目标的个性化治疗计划至关重要。本文将回顾目前的文献，在怀孕和哺乳期间使用疾病改善抗风湿药物和生物制剂，提供医疗保健专业人员最新的信息。妊娠期慢性风湿性疾病的适当医疗管理可以预防母体终末器官损伤，并最大限度地减少疾病对妊娠结局的不良影响。
Chronic rheumatic diseases often occur in women of reproductive age and the impact pregnancy has on rheumatic disease often varies depending on the condition. Medical management of rheumatic diseases during pregnancy may prevent joint or organ damage and minimize the adverse effects of the disease itself on pregnancy outcomes. Each patient requires individual assessment to control disease activity, while minimizing or avoiding medications with potential maternal or fetal toxicity. An open discussion with shared decision-making between patients, obstetricians, rheumatologists, and pharmacists is imperative to create an individualized treatment plan that meets patient’s goals. This paper will review the current literature available for use of disease modifying anti-rheumatic drugs and biologics during pregnancy and lactation, providing healthcare professionals with the most up-to-date information available. Appropriate medical management of chronic rheumatic disease during pregnancy can prevent maternal end-organ damage and minimize the adverse effects of the disease on pregnancy outcomes.